We build Respiro, the connected respiratory platform for inhaled medicine. Smart inhaler sensors and a regulated data layer turn everyday inhaler use into adherence, technique and real-world evidence. It's built for the people who breathe easier with them, and for the pharma, clinicians and partners who build on the data.
Make the medicine, deliver the care, build the technology or study the outcomes: between visits, everyone is working blind. Respiro is built to close that gap.
Doses get missed and mistimed, and no one knows until control slips, or an attack lands someone in hospital.
Most people don't use their inhaler correctly, so much of the dose never reaches the lungs, and the mistake goes unseen.
What happens between appointments is invisible: to patients, to clinicians, and to the brands that made the therapy.
Connected respiratory care is no longer a pilot. It's infrastructure. Respiro is that stack: inhaler sensors, a regulated cloud, and the apps built on it. Take it end to end, or plug in at any layer.
Capture every dose (its timing and inhalation quality) from a wide range of inhalers, then stream it to any app: ours or a partner's.
Turn raw inhaler signal into the metrics that drive decisions, on a secure, medical-grade cloud that's built to build on.
Where the insight reaches people (patients, clinicians and pharma) through our apps, or your own front end with Respiro underneath.
One platform. Take it whole, or just the engine.
We build the sensor (even a custom one for your therapy), power it with our algorithms and regulated cloud, and deliver it to patients through our own apps. The Respiro app people hold today is exactly this.
See the full platformAlready have an app or digital therapeutic? Embed the Respiro Connect SDK and pull our APIs: you keep the experience, we're the connected-respiratory engine underneath. Integration by design.
See integration optionsClinically validated in earlier Respiro studies. See the evidence.
However you take the platform, what you build on it depends on who you are. Each team starts from the same validated, regulated foundation, then takes it where their work needs it to go.
Digital companion apps, real-world evidence and drug-device combination products that extend the life and value of an inhaled therapy.
Explore pharma solutionsRemote monitoring, exacerbation-risk flags and clinic-ready reports that make every respiratory consultation shorter and better informed.
Explore clinical solutionsThe Respiro Connect SDK, open APIs and white-label options to embed our connected-inhaler intelligence inside your own digital-health product or device.
Explore integrationObjective, time-stamped adherence and inhaler-technique data for clinical trials, digital endpoints and academic studies, with the rigour to stand up to peer review.
Explore collaborationsIn earlier Respiro studies, patients who could see their own adherence and technique had better outcomes, and lower costs from poorly-controlled disease. The numbers rest on years of peer-reviewed research and a certified quality system.
At Respiratory Drug Delivery 2026, a pharmacy-led evaluation in asthma and COPD found nearly three in four patients improved their inhalation technique with Respiro — across three different inhalers.
Read the resultsWith ARTES 4.0 and PNRR backing, we brought CFD simulation and automation to the next generation of inhaler sensors: up to 40% less development time, so better connected hardware reaches patients sooner.
Read moreA peer-reviewed study tested how accurately RS01X reads each inhalation against a laboratory reference. Across 97 people with asthma, COPD and healthy lungs, agreement was near-perfect.
Read moreTell us a little about your organisation and what you're trying to do. We'll point you to the right part of the platform, and the right person.
We'll only use your details to respond.
Thanks, we'll be in touch shortly.